Literature DB >> 22534621

Tumor necrosis factor-α-mediated downregulation of the cystic fibrosis transmembrane conductance regulator drives pathological sphingosine-1-phosphate signaling in a mouse model of heart failure.

Anja Meissner1, Jingli Yang, Jeffrey T Kroetsch, Meghan Sauvé, Hendrik Dax, Abdul Momen, M Hossein Noyan-Ashraf, Scott Heximer, Mansoor Husain, Darcy Lidington, Steffen-Sebastian Bolz.   

Abstract

BACKGROUND: Sphingosine-1-phosphate (S1P) signaling is a central regulator of resistance artery tone. Therefore, S1P levels need to be tightly controlled through the delicate interplay of its generating enzyme sphingosine kinase 1 and its functional antagonist S1P phosphohydrolase-1. The intracellular localization of S1P phosphohydrolase-1 necessitates the import of extracellular S1P into the intracellular compartment before its degradation. The present investigation proposes that the cystic fibrosis transmembrane conductance regulator transports extracellular S1P and hence modulates microvascular S1P signaling in health and disease. METHODS AND
RESULTS: In cultured murine vascular smooth muscle cells in vitro and isolated murine mesenteric and posterior cerebral resistance arteries ex vivo, the cystic fibrosis transmembrane conductance regulator (1) is critical for S1P uptake; (2) modulates S1P-dependent responses; and (3) is downregulated in vitro and in vivo by tumor necrosis factor-α, with significant functional consequences for S1P signaling and vascular tone. In heart failure, tumor necrosis factor-α downregulates the cystic fibrosis transmembrane conductance regulator across several organs, including the heart, lung, and brain, suggesting that it is a fundamental mechanism with implications for systemic S1P effects.
CONCLUSIONS: We identify the cystic fibrosis transmembrane conductance regulator as a critical regulatory site for S1P signaling; its tumor necrosis factor-α-dependent downregulation in heart failure underlies an enhancement in microvascular tone. This molecular mechanism potentially represents a novel and highly strategic therapeutic target for cardiovascular conditions involving inflammation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22534621     DOI: 10.1161/CIRCULATIONAHA.111.047316

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  26 in total

Review 1.  The emerging alliance of sphingosine-1-phosphate signalling and immune cells: from basic mechanisms to implications in hypertension.

Authors:  Nicholas Don-Doncow; Yun Zhang; Hana Matuskova; Anja Meissner
Journal:  Br J Pharmacol       Date:  2018-07-03       Impact factor: 8.739

Review 2.  Cerebral artery myogenic reactivity: The next frontier in developing effective interventions for subarachnoid hemorrhage.

Authors:  Darcy Lidington; Jeffrey T Kroetsch; Steffen-Sebastian Bolz
Journal:  J Cereb Blood Flow Metab       Date:  2017-11-14       Impact factor: 6.200

3.  CFTR and sphingolipids mediate hypoxic pulmonary vasoconstriction.

Authors:  Christoph Tabeling; Hanpo Yu; Liming Wang; Hannes Ranke; Neil M Goldenberg; Diana Zabini; Elena Noe; Adrienn Krauszman; Birgitt Gutbier; Jun Yin; Michael Schaefer; Christoph Arenz; Andreas C Hocke; Norbert Suttorp; Richard L Proia; Martin Witzenrath; Wolfgang M Kuebler
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-17       Impact factor: 11.205

Review 4.  Regulation of vascular tone and arterial blood pressure: role of chloride transport in vascular smooth muscle.

Authors:  Christian A Hübner; Björn C Schroeder; Heimo Ehmke
Journal:  Pflugers Arch       Date:  2015-01-16       Impact factor: 3.657

Review 5.  Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies.

Authors:  J Jacquot; M Delion; S Gangloff; J Braux; F Velard
Journal:  Osteoporos Int       Date:  2015-10-02       Impact factor: 4.507

6.  High-density lipoprotein: NO failure in heart failure.

Authors:  Ali Javaheri; Daniel J Rader
Journal:  Circ Res       Date:  2013-12-06       Impact factor: 17.367

Review 7.  Cl⁻ channels in smooth muscle cells.

Authors:  Simon Bulley; Jonathan H Jaggar
Journal:  Pflugers Arch       Date:  2014-05       Impact factor: 3.657

Review 8.  Targeting sphingosine-1-phosphate signaling in lung diseases.

Authors:  David L Ebenezer; Panfeng Fu; Viswanathan Natarajan
Journal:  Pharmacol Ther       Date:  2016-09-13       Impact factor: 12.310

Review 9.  The TNF-α/sphingosine-1-phosphate signaling axis drives myogenic responsiveness in heart failure.

Authors:  Jeffrey T Kroetsch; Steffen-Sebastian Bolz
Journal:  J Vasc Res       Date:  2013-04-16       Impact factor: 1.934

10.  Diaphragm dysfunction in heart failure is accompanied by increases in neutral sphingomyelinase activity and ceramide content.

Authors:  Hyacinth M Empinado; Gergana M Deevska; Mariana Nikolova-Karakashian; Jeung-Ki Yoo; Demetra D Christou; Leonardo F Ferreira
Journal:  Eur J Heart Fail       Date:  2014-03-04       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.